Home > Category > Signaling Pathways > Protein Tyrosine Kinase/RTK > Bcr-Abl > Rebastinib (DCC-2036)

Rebastinib (DCC-2036)

ChemLeader 98+%
Catalog No:CL2536 CAS No.:1020172-07-9 MDLNo: Formula:C30H28FN7O3 MW:553.59
Size Availability Price(USD) VIP Price (USD) Quantity
5 mg 3-5days $155.00 Visible after login
- +
10 mg 3-5days $250.00 Visible after login
- +
25 mg 3-5days $450.00 Visible after login
- +

Chemical safety data sheet(MSDS)

Download MSDS
  • Product Overview
  • Related documents
  • Product details
  • Related literature
Product Overview
Product Name Rebastinib (DCC-2036)
CAS1020172-07-9
FormulaC30H28FN7O3
MW553.59
AppearanceWhite to off-white powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Product details

Rebastinib (formerly also known as DCC-2036), a novel, potent and orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity, is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50s of 0.8 nM and 4 nM. It also inhibits other kinases such as SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and has low activity towards c-Kit. DCC-2036 inhibits ABL1 through forcing the kinase domains into inhibitor-bound, inactive Type II conformations. In cellular assay, DCC-2036 inhibits the proliferation of Ba/F3 and K562 cells with IC50 values of 5.4nM and 5.5nM, respectively.

Related literature
Sorry, there is no relevant literature
Related
Sorry, no related items
Service
ChemLeader
021-58180488
Online service time: 9:00-18:00 on weekdays